[go: up one dir, main page]

PE20200383A1 - Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados - Google Patents

Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados

Info

Publication number
PE20200383A1
PE20200383A1 PE2019001790A PE2019001790A PE20200383A1 PE 20200383 A1 PE20200383 A1 PE 20200383A1 PE 2019001790 A PE2019001790 A PE 2019001790A PE 2019001790 A PE2019001790 A PE 2019001790A PE 20200383 A1 PE20200383 A1 PE 20200383A1
Authority
PE
Peru
Prior art keywords
purified
terpens
compositions including
cannabinoids
selected compositions
Prior art date
Application number
PE2019001790A
Other languages
English (en)
Inventor
Kurt Levy
Jonathan Michael Cooper
Jonathan Reed Martin
Brian Geoffrey Reid
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/616,874 external-priority patent/US20170266153A1/en
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of PE20200383A1 publication Critical patent/PE20200383A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

Referido a una composicion que comprende un primer cannabinoide purificado; y un compuesto elegido de un segundo cannabinoide purificado o un primer terpeno purificado. En donde el primer terpeno purificado se elige entre 7,8-dihidro-alfa-ionona, acetanisol, limoneno, entre otros; el primer cannabinoide purificado se elige entre acido cannabigerolico (CBGA), cannabigerol (CBG), tetrahidrocannabinol (THC), entre otros. En donde dicha composicion tiene una pureza superior al 80 % y su formulacion comprende combinaciones intencionalmente disenadas de proporciones y concentraciones no naturales.
PE2019001790A 2017-03-01 2018-03-01 Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados PE20200383A1 (es)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201762465688P 2017-03-01 2017-03-01
US201762469415P 2017-03-09 2017-03-09
US201762475153P 2017-03-22 2017-03-22
US201762477990P 2017-03-28 2017-03-28
US201762489360P 2017-04-24 2017-04-24
US201762490465P 2017-04-26 2017-04-26
US201762490567P 2017-04-26 2017-04-26
US201762491160P 2017-04-27 2017-04-27
US201762491175P 2017-04-27 2017-04-27
US201762491980P 2017-04-28 2017-04-28
US201762491899P 2017-04-28 2017-04-28
US201762509651P 2017-05-22 2017-05-22
US201762510229P 2017-05-23 2017-05-23
US201762510660P 2017-05-24 2017-05-24
US201762510672P 2017-05-24 2017-05-24
US201762511218P 2017-05-25 2017-05-25
US15/616,874 US20170266153A1 (en) 2015-02-27 2017-06-07 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
PCT/US2018/020440 WO2018160827A1 (en) 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes

Publications (1)

Publication Number Publication Date
PE20200383A1 true PE20200383A1 (es) 2020-02-24

Family

ID=63370542

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001790A PE20200383A1 (es) 2017-03-01 2018-03-01 Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados

Country Status (10)

Country Link
EP (1) EP3589129A4 (es)
CN (1) CN110582206A (es)
AU (1) AU2018227544A1 (es)
BR (1) BR112019018088A2 (es)
CA (1) CA3054690A1 (es)
CO (1) CO2019009413A2 (es)
IL (1) IL268929A (es)
MX (1) MX2019010370A (es)
PE (1) PE20200383A1 (es)
WO (1) WO2018160827A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458906B2 (en) 2018-01-23 2025-11-04 High Sierra Technologies, Inc. Methods of modifying a naturally occurring cannabis raw plant material, a purified cannabis product from a naturally occurring cannabis raw plant material, and a modified cannabis product from a naturally occurring cannabis raw plant material
US10737198B2 (en) 2018-01-23 2020-08-11 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
IL266151A (en) * 2019-04-18 2019-07-31 Kanabo Res Ltd Dilute for the cannabinoid preparations
CA3148236A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
CN114980882A (zh) * 2019-11-26 2022-08-30 乐康瑞德有限公司 大麻素和番茄红素抗炎协同组合
CN115605289A (zh) * 2020-04-29 2023-01-13 利加尔有限合伙公司（Nz） 印迹聚合物及其使用方法
EP4188915A1 (en) * 2020-07-27 2023-06-07 Canopy Growth Corporation Methods of synthesizing cannabielsoin and analogs thereof
US20240342197A1 (en) * 2021-01-29 2024-10-17 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
WO2023245185A1 (en) * 2022-06-17 2023-12-21 New Growth Brands, Inc. Compositions comprising cannabinoids and methods of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
CA2931039C (en) * 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MX2017010872A (es) * 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.

Also Published As

Publication number Publication date
CN110582206A (zh) 2019-12-17
CO2019009413A2 (es) 2019-09-09
EP3589129A1 (en) 2020-01-08
IL268929A (en) 2019-10-31
AU2018227544A1 (en) 2019-08-29
CA3054690A1 (en) 2018-09-07
BR112019018088A2 (pt) 2020-03-24
WO2018160827A1 (en) 2018-09-07
EP3589129A4 (en) 2020-11-25
MX2019010370A (es) 2019-10-22

Similar Documents

Publication Publication Date Title
PE20200383A1 (es) Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados
PE20190318A1 (es) Composicion administrable oralmente
EA202092582A1 (ru) Препараты каннабидиола и их применение
SV1999000072A (es) Composiciones estabilizadas
MX2020003934A (es) Uso de cannabidiol en combinacion con agonistas del receptor 5-ht2b o anfetamina en el tratamiento de la epilepsia.
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
BRPI0717970C1 (pt) composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto
AR089211A1 (es) Fluido de fracturacion acuoso de baja viscosidad
CL2017001983A1 (es) Composiciones farmacéuticas para terapia combinada.
CO6220926A2 (es) Formulacion farmaceutica topica para la aplicacion de un farmaco antiinflamatorio no esferoidal (nsaid)
CR11316A (es) Derivado de uracilo o timina para el tratamiiento de la hepatitis c.
BR112014029754B1 (pt) soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição
BRPI0410660A (pt) derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
AR059927A1 (es) Metodos para la estabilizacion de composiciones inestables a la oxidacion y composiciones oftalmicas estabilizadas
PE20200478A1 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion
CL2023001745A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
CL2023001747A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
BR112018012952A2 (pt) composições para higiene pessoal
UY38941A (es) Nuevas sulfiliminas o sulfoximinas que contienen compuestos heterocíclicos fungicidas
BR112013019394A2 (pt) uso de um agente
CO2023000239A2 (es) Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas
CL2019002516A1 (es) Composiciones cosméticas para el cuidado de la piel.
BR112013022975A2 (pt) composições contendo copolímeros
MX2023006281A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
BR0318411A (pt) desinfetante mucoso não tóxico contendo álcool isopropìlico, óleo de gergelim, aloés e óleo de limão